Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avalglucosidase alfa in infantile-onset Pompe disease
NCT03019406Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Oct 2017
- Primary completion
- Sep 2019
- Modality
- Replacement Enzymes
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of avalglucosidase alfa in Pompe disease (4 cohorts), sponsored by Sanofi. Primary endpoints: Treatment-emergent Adverse Events at 25 weeks and Infusion-associated Reactions at 25 weeks. Started Oct 2017; status: active, not recruiting.
02
Drugs
avalglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NCT03019406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03019406.